Collegium Pharmaceutical, Inc (COLL)
- Sector
- Pharmaceuticals
- Last price
- $23.23
- As of
Kresmion compiles this page from COLL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
COLLEGIUM PHARMACEUTICAL, INC (COLL): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-19.
See the full COLL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for COLL on one page. Preview it with sample data, then open it live with a free account.
Preview the COLL dossierActive events for COLL
- high13F: funds added
3 tracked funds increased COLL this 2026Q2, institutional consensus
- mediumEarnings above estimates
Q2-2026: Beat consensus by 9.7%, EPS $1.92 vs $1.7495 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 75% of COLL (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +69% to COLL (2026Q2)
- medium13F: new position
Point72 Asset Management, L.P. new position in COLL
FREE, NO ACCOUNT
Every event on COLL, as it fires
You are seeing 5 of 12 events recorded on COLL since 2026-05-29.
The five above landed across 3 days. The other 7 were recorded on 2 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in COLL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 19459J104 · 2026Q2 | $49.5M | 0.07% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 19459J104 · 2026Q2 | $26.7M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 19459J104 · 2026Q2 | $12.2M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 19459J104 · 2026Q2 | $4.1M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 19459J104 · 2026Q2 | $3.9M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 19459J104 · 2026Q2 | $2.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, COLL
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
COLL against its peers
COLL's operating margin of 23.0% ranks in the 82nd percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | COLL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 781M USD | 403M USD | 78 | 19 |
| Gross margin | 59.3% | 74.0% | 32 | 10 |
| Operating margin | 23.0% | 2.6% | 83 | 19 |
| Net margin | 8.1% | 0.2% | 73 | 19 |
| Return on equity | 20.8% | -14.3% | 89 | 22 |
| P / E | 13.4x | 14.9x | 39 | 8 |
Peers (25): ESPR.D, ALMS, ANRO, ACRS, AMPH, OMER, NKTR, PCRX, INVA, GPCR, PAHC, OCUL, NUVB, ANIP, AVIR, TRVI, XERS, FULC, BIOA, HRMY, ACB, SUPN, SIGA, BHC, TARS. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (COLL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow COLL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to COLL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.